NIH Clinical Research Studies

Protocol Number: 03-DK-0170

Active Accrual, Protocols Recruiting New Patients

Title:
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Anemia, Thalassemia, and Diamond Blackfan Anemia
Number:
03-DK-0170
Summary:
People with severe congenital anemias, such as sickle cell anemia, thalassemia, and Diamond Blackfan anemia, have been cured with bone marrow transplantation (BMT). The procedure, however, is limited to children younger than the age of 16 because the risks are lower for children than for adults.

The purpose of this study is to explore the use of a BMT regimen that, instead of chemotherapy, uses a low dose of radiation, combined with two immunosuppressive drugs. This type BMT procedure is described as nonmyeloablative, meaning that it does not destroy the patient's bone marrow. It is hoped that this type of BMT will be safe for patients normally excluded from the procedure because of their age and other reasons.

To participate in this study, patients must be between the ages of 18 and 65 and have a sibling who is a well-matched stem-cell donor. Beyond the standard BMT protocol, study participants will undergo additional procedures. The donor will receive G-CSF by injection for five days; then his or her stem cells will be collected and frozen one month prior to BMT. Approximately one month later, the patient will be given two immune-suppressing drugs, Campath 1-H and Sirolimus, as well as a single low dose of total body irradiation and then the cells from the donor will be infused.

Prior to their participation in this study, patients will undergo the following evaluations: a physical exam, blood work, breathing tests, heart-function tests, chest and sinus x-rays, and bone-marrow sampling.

Sponsoring Institute:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruitment Detail
Type: Active Accrual Of New Subjects
Gender: Male & Female
Referral Letter Required: No
Population Exclusion(s): Children

Eligibility Criteria:
INCLUSION CRITERIA:

RECIPIENTS:

Patients with Hb SS, SC, or Sb-thalo at high risk for disease related mortality or morbidity as defined by having one or more of the following:

- a previous neurologic event (either symptomatic or found by imaging alone),

- more than 2 painful crises per year for the last 2 years each requiring hospitalization,

- a previous acute chest syndrome,

- evidence of renal damage

- red cell alloimmunization,

- stage I or II sickle chest, (Stage I patients have normal oxygen saturation but 80% of predicted normal pulmonary function tests. Stage II patients also have normal oxygen saturation but 60% of predicted normal pulmonary function tests.)

- osteonecrosis of multiple joints

- pulmonary hypertension as measured by a TRV jet of greater than 2.5m/s

and

- having failed hydroxyurea, as defined by a failure to achieve a hematologic response and/or clinical response where clinical/hematologic response is defined as a significant decrease in the number of crises experienced after a 6 month trial or a 2-3 fold increase in the hemoglobin F level unless has renal insufficiency preventing hydroxyurea use, or indication for transplant is or includes a neurologic event.

or

Patients with transfusion dependent Diamond Blackfan anemia

or

Patients with Thalassemia with Class II or III Iron overload

Ages 18- 65

6/6 HLA matched family donor available

Ability to comprehend and willing to sign an informed consent

Negative Serum B-HCG

INCLUSION CRITERIA:

DONOR

6/6 HLA identical family donor

Age greater than or equal to 18

Fit to receive G-CSF and give peripheral blood stem cells (normal blood counts, normotensive and no history of stroke)

Ability to comprehend and willing to sign an informed consent; assent obtained from minors

EXCLUSION CRITERIA:

RECIPIENT

(any of the following would exclude the subject from participating)

Age less than 18 years or greater than 65 years

ECOG performance status of 3 or more.

Diffusion capacity of carbon monoxide (DLCO) less than 60% predicted.

Left ventricular ejection fraction: less than 40%.

Transaminases greater than 5x upper limit of normal

Psychiatric disorder or mental deficiency severe enough as to make compliance with the BMT treatment unlikely, and making informed consent impossible.

Major anticipated illness or organ failure incompatible with survival from PBSC transplant.

Pregnant or lactating

EXCLUSION CRITERIA:

DONOR:

(any of the following would exclude the donor from participating)

Age less than 18

Pregnant or lactating

Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia)

HIV positive

Hemoglobin SS, SC, or Sbeta thal0, or beta thalassemia intermedia

Abnormal Red Cell Adenosine Deaminase level

Special Instructions: Currently Not Provided
Keywords:
Stem Cell Transplant
Low Dose Radiation
Alemtuzumab (Campath)
Sirolimus (Rapamune)
Donor Apheresis
Graft-Versus-Host Disease
Graft-Versus-Marrow
Host-Donor Chimerism
Peripheral Blood Stem Cells
Low Dose Irradiation
Recruitment Keywords:
Sickle Cell Anemia
SCA
Thalassemia
Diamond-Blackfan Anemia
DBA
Conditions:
Congenital Hemolytic Anemia
Diamond-Blackfan Anemia
Investigational Drug(s):
None
Investigational Device(s):
None

Contacts:
Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:
Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell

disease. Blood. 2000 Oct 1;96(7):2369-72. PMID: 11001885

Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 9;330(23):1639-44. PMID: 7993409

Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

N Engl J Med. 1995 May 18;332(20):1317-22. PMID: 7715639

Active Accrual, Protocols Recruiting New Patients

If you have:


Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home


Clinical Center LogoWarren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/19/2004

Search The Studies Help Questions